Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria
Prashant Bhangui,Sanjiv Saigal,Dheeraj Gautam,Tarun Piplani,Narendra Choudhary,Rohan Chaudhary,Sanjay Yadav,S. Thiagarajan,Amit Rastogi,Neeraj Saraf,Samiran Nundy,A.S. Soin
DOI: https://doi.org/10.1002/lt.25956
2021-01-29
Liver Transplantation
Abstract:<p>Conventional selection criteria for liver transplantation in patients with hepatocellular carcinoma (HCC) based on tumour size and number alone, do not consider vital surrogates of tumor biology like alpha‐fetoprotein (AFP) and tumour FDG‐18 PET avidity. We follow an expanded selection criteria for living donor liver transplantation (LDLT) in patients with cirrhosis and HCC (HCC‐cirr): no extrahepatic disease, no major vascular invasion, irrespective of tumour size and number. We analyzed survival outcomes in 405 HCC‐cirr patients (51% beyond Milan, 43% beyond UCSF criteria), and predictors of HCC recurrence. The 5‐yr overall (OS) and recurrence‐free (RFS) were 64% and 70%, respectively. Recurrence rate in 300 patients (excluding postoperative deaths, and those with deficient preoperative data) was 17.6%, with 3 preoperatively available factors predicting worse RFS; pre‐LT AFP ≥100 ng/ml (p=0.005, HR:2.190), tumour burden beyond UCSF criteria (p=0.001, HR:2.640), and FDG‐18 PET avidity (p=0.004, HR:2.442). Tumour FDG‐18 PET avidity and AFP ≥100 mg/ml predicted OS. A prognostic model based on the number of, and combination of the above pre operative risk factors for recurrence, was developed using a competing‐risk RFS model, and helped stratify patients into 3 risk groups: low risk (none or a single risk factor present, 9.3% recurrence), moderate risk (AFP≥100 ng/ml and FDG‐18 PET avidity, or beyond UCSF tumour and FDG‐18 PET avidity, 25% recurrence), and high risk (AFP≥100 ng/ml and beyond UCSF, or presence of all 3 risk factors, 46% recurrence). <b><i>Conclusion</i></b><i>:</i> Acceptable post‐LDLT long term outcomes were achieved using our expanded selection criteria. Our prognostic model to predict recurrence based on pre operative biological and morphological factors could guide pre‐transplant management (downstaging vs. upfront LDLT), with the aim of reducing post‐LDLT recurrence.</p>
gastroenterology & hepatology,surgery,transplantation